Topic cluster
Viral GLP-1 Claims: Fact-Checks & Evidence Reviews
Eight WLR articles carry Schema.org ClaimReview metadata — meaning the verdict (True / Mostly True / Mixture / False) is machine-readable and the article is eligible for Google's Fact Check carousel and Gemini's evidence-evaluator surface. They cover the most-searched viral claims about GLP-1 drugs: the 'Ozempic baby' fertility phenomenon, the 'snap back' rebound after stopping, alleged personality change, hair loss, muscle loss, off-label use, psoriasis, and contraceptive interactions. Each verdict is anchored in PubMed-indexed primary research and FDA-label citations.
8 research articles in this cluster · last updated 2026-05-23
Ozempic Baby: Fertility, Pregnancy & Contraception on GLP-1 — Evidence Review
TikTok 'Ozempic baby' = three combined mechanisms: weight loss restoring PCOS ovulation, tirzepatide (NOT semaglutide) reducing oral contraceptive absorption, and GI side effects. Ozempic + Wegovy require a 2-month washout before planned pregnancy per FDA label.
Ozempic Snap Back: Anti-Rebound TikTok Term and the Real Evidence
"Ozempic snap back" is TikTok shorthand for rapid weight regain after stopping. STEP-4 and SURMOUNT-4 randomized trials show patients regain about two-thirds of lost weight within 12 months. Obesity is a chronic disease — long-term GLP-1 therapy is the standard.
Ozempic Personality Change & Anhedonia: Honest Evidence Review
Patient reports of reward blunting on semaglutide — food, alcohol, compulsive behaviors — map onto GLP-1 receptor signaling in the VTA + nucleus accumbens. Wang 2024 found no suicidality signal. Severe anhedonia plus depressed mood still warrants prescriber contact.
Ozempic Hair Loss & Telogen Effluvium: Honest Evidence Review
Hair loss on Ozempic is real but it is telogen effluvium, a temporary rapid-weight-loss shedding pattern, not direct drug toxicity. Wegovy 2.4 mg label: 3.3% alopecia (4% women, 0.9% men) vs 1.0% placebo. Starts 2-3 months in, peaks 3-6 months, resolves spontaneously within 6-12 months as weight stabilizes.
Ozempic Muscle Loss & Lean Mass Protection: Honest Evidence Review
Muscle loss on Ozempic is real but proportional to weight-loss rate, not unique to the drug. SURMOUNT-1 DXA: ~25-40% of weight lost is lean tissue, comparable to non-pharmacological rapid loss. Resistance training 2-3x/week + 1.2-1.6 g/kg protein is the protective intervention.
Ozempic for Psoriasis & Eczema: Emerging Anti-Inflammatory Evidence Review
Ozempic is NOT FDA-approved for psoriasis or eczema. Liraglutide case series suggested PASI improvement in T2D+psoriasis patients, but the only placebo-controlled RCT in glucose-tolerant patients (Faurschou 2015) was negative — weight loss itself is the mechanism.
Ozempic Without Diabetes: Off-Label Use for Weight Loss Evidence Review
Ozempic is FDA-approved only for type 2 diabetes — off-label for weight loss is legal under 21 USC 396 but rarely insurance-covered. Wegovy is the on-label equivalent (same semaglutide, 2.4 mg vs 2.0 mg max). SELECT trial extends CV safety to non-diabetic obese adults.
Ozempic and Birth Control: Why Semaglutide Has No OC Warning — Evidence Review
Ozempic and Wegovy (semaglutide) carry NO oral-contraceptive warning on the FDA label — only Mounjaro and Zepbound (tirzepatide) do. The Kapitza 2015 PK study showed semaglutide does not meaningfully reduce ethinyl estradiol or levonorgestrel exposure.